PI3Kβ and δ inhibitor 20a
CAS No. 1842380-77-1
PI3Kβ and δ inhibitor 20a ( —— )
Catalog No. M12847 CAS No. 1842380-77-1
A potent, highly selective PI3Kβ/δ inhibitor with IC50 of 7.8/5.3 nM respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 873 | Get Quote |
|
50MG | 1782 | Get Quote |
|
100MG | 2250 | Get Quote |
|
200MG | Get Quote | Get Quote |
|
500MG | Get Quote | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePI3Kβ and δ inhibitor 20a
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, highly selective PI3Kβ/δ inhibitor with IC50 of 7.8/5.3 nM respectively.
-
DescriptionA potent, highly selective PI3Kβ/δ inhibitor with IC50 of 7.8/5.3 nM respectively, with liitle to no activity on PI3Kα/γ (IC50=850/>10,000 nM); inhibits the phosphorylation of AKT1 Ser473 in PI3K-dependent cell lines with EC50 of 3.4-7.3 nM, inhibits AKT Ser473 phosphorylation and cell viability of LNCaP tumor cells with EC50 of 7.3 nM and GI50 of 38 nM; demonstrates efficacy in human PTEN-deficient LNCaP prostate carcinoma xenograft tumor model.
-
Synonyms——
-
PathwayPI3K/Akt/mTOR signaling
-
TargetPI3K
-
RecptorPI3K
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1842380-77-1
-
Formula Weight450.26
-
Molecular FormulaC17H14Cl2FN9O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESFC1=CC(Cl)=C(N=C([C@@H](NC2=C(Cl)C(N)=NC(N)=N2)C)N(C3=NNC=C3)C4=O)C4=C1
-
Chemical Name(S)-8-chloro-2-(1-((2,6-diamino-5-chloropyrimidin-4-yl)amino)ethyl)-6-fluoro-3-(1H-pyrazol-3-yl)quinazolin-4(3H)-one
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Perreault S, et al. J Med Chem. 2017 Feb 23;60(4):1555-1567.
molnova catalog
related products
-
PI3Kα-IN-4h
PI3Kα-IN-1 is a potent, selective, ATP-competitive dual PI3Kα/mTOR inhibitor with IC50 of 0.5/104 nM respectively.
-
DS-7423
DS-7423 is a novel potent, small-molecule dual inhibitor of PI3K/mTOR.
-
Idelalisib
Idelalisib is a selective inhibitor of p110δ(IC50 : 2.5 nM; in cell-free assays); shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.